Why pay $100B for AstraZeneca? Let Pfizer’s CEO count the reasons

Tracy Staton

Pfizer considers itself a megamerger expert. And it's hoping to prove that with another megadeal–a $ 100 billion-or-so buyout of . After last week's headlines about a possible buyout, both companies confirm that Pfizer is hot to trot and ready to parley.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS